Subscribe To
OVID / Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
OVID News
By GlobeNewsWire
September 20, 2023
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that more_horizontal
By Zacks Investment Research
August 4, 2023
Ovid Therapeutics (OVID) Reports Q2 Loss, Lags Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to lo more_horizontal
By Seeking Alpha
June 13, 2023
Ovid Therapeutics: Bullish Outlook Strengthened By Positive 2-Year Open-Label Trial Results
Ovid Therapeutics' TAK-935 has a high potential for positive Phase 3 clinical trial results for both Dravet Syndrome (DS) and Lennox-Gastaut Syndrome more_horizontal
By Zacks Investment Research
May 5, 2023
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to lo more_horizontal
By Zacks Investment Research
April 12, 2023
Ovid Therapeutics (OVID) Upgraded to Buy: Here's What You Should Know
Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy more_horizontal